Sofinnova closes €650m healthcare fund for early-stage ventures

Sofinnova Partners has closed its latest Sofinnova Capital XI fund, aimed astatine supporting early-stage healthcare companies successful the US and Europe, astatine €650m ($750m) supra its archetypal target.

The money volition absorption connected aesculapian exertion and biopharmaceutical companies that question to conscionable pressing unmet objective needs, leveraging Sofinnova’s multi-strategy level and concern team.

It volition leverage the acquisition of partners Maina Bhaman, Anta Gkelou, Karl Naegler, Antoine Papiernik, Henrijette Richter and Graziano Seghezzi.

The money volition enactment successful some follow-on and archetypal rounds, continuing Sofinnova’s absorption connected early-stage biotech and medtech ventures crossed its halfway markets.

The money has secured commitments from a worldwide web of organization investors, including foundations, corporates, household offices, security companies, sovereign wealthiness funds and pharmaceutical companies.

Investors came from Europe, Asia, North America and the Middle East, with a bulk of returning constricted partners alongside caller investors indicating continued involvement successful Sofinnova’s way grounds and strategy.

Sofinnova Partners managing spouse and president Antoine Papiernik stated: “This fundraising marks a pivotal infinitesimal for Sofinnova. It gives america the firepower to treble down connected early-stage opportunities and reinforces our uniquely collaborative, science-driven concern approach.

“We’re excited to proceed backing visionary entrepreneurs and advancing the adjacent question of breakthroughs successful subject and medicine to bring them to patients worldwide. Achieving this milestone successful today’s volatile fundraising situation speaks to the spot of our exemplary and the assurance our investors proceed to spot successful us.”

Sofinnova Capital XI is presently deploying capital, having invested successful respective portfolio companies.

Sofinnova is simply a European task superior institution specialising successful beingness sciences, with a peculiar absorption connected sustainability and healthcare. Its squad combines medical, concern and technological expertise.

"Sofinnova closes €650m healthcare money for early-stage ventures" was primitively created and published by Pharmaceutical Technology, a GlobalData owned brand.

The accusation connected this tract has been included successful bully religion for wide informational purposes only. It is not intended to magnitude to proposal connected which you should rely, and we springiness nary representation, warranty oregon guarantee, whether explicit oregon implied arsenic to its accuracy oregon completeness. You indispensable get nonrecreational oregon specializer proposal earlier taking, oregon refraining from, immoderate enactment connected the ground of the contented connected our site.